In the wake of the increase in Current Liabilities in the second quarter 2024, Quick Ratio fell to 0.11 a new company low.

Within Major Pharmaceutical Preparations industry 442 other companies have achieved higher Quick Ratio than Agile Therapeutics Inc in second quarter 2024. While Quick Ratio total ranking in the second quarter 2024 has deteriorated compared to the prior quarter from 2331 to 3539.

Explain Quick Ratio?
How much Cash & cash equivalents AGRX�s has?
What are AGRX�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

AGRX Quick Ratio	(Jun 30 2024) Q2	(Mar 31 2024) Q1	(Dec 31 2023) Q4	(Sep 30 2023) Q3	(Jun 30 2023) Q2
Y / Y Current Liabilities Change	71.32 %	13.82 %	55.2 %	50.5 %	-46.81 %
Y / Y Cash & cash equivalent Change	2.26 %	-40.96 %	-51.26 %	-53.25 %	-78.62 %
Quick Ratio MRQ	0.11	0.12	0.12	0.16	0.18
AGRX's Total Ranking	# 3539	# 2331	# 2719	# 3402	# 3377
Seq. Current Liabilities Change	24.52 %	1.38 %	18.47 %	14.56 %	-17.28 %
Seq. Cash & cash equivalent Change	8.91 %	2.27 %	-11 %	3.16 %	-37.12 %

Quick Ratio second quarter 2024 Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 443
Healthcare Sector	# 896
Overall Market	# 3539

Quick Ratio Statistics
High	Average	Low
35.05	5.21	0.11
(Mar 31 2020)		(Jun 30 2024)

Financial Statements
Agile Therapeutics Inc's Current Liabilities	$ 26 Millions	Visit AGRX's Balance sheet
Agile Therapeutics Inc's Cash & cash equivalent	$ 3 Millions	Visit AGRX's Balance sheet
Source of AGRX's Sales		Visit AGRX's Sales by Geography

Cumulative Agile Therapeutics Inc's Quick Ratio

AGRX's Quick Ratio for the trailling 12 Months

AGRX Quick Ratio	(Jun 30 2024) 12 Months	(Mar 31 2024) 12 Months	(Dec 31 2023) 12 Months	(Sep 30 2023) 12 Months	(Jun 30 2023) 12 Months
Y / Y Current Liabilities TTM Growth	45.45 %	3.26 %	-9.46 %	-32.25 %	-37.01 %
Y / Y Cash & cash equivalent TTM Growth	-41.45 %	-62.46 %	-55.1 %	-63.54 %	-63.27 %
Quick Ratio TTM	0.13	0.15	0.18	0.24	0.32
Total Ranking TTM	# 3642	# 2421	# 3668	# 2831	# 2844
Seq. Current Liabilities TTM Growth	14.62 %	3.54 %	11.41 %	10 %	-18.63 %
Seq. Cash & cash equivalent TTM Growth	0.58 %	-14.35 %	-17.54 %	-17.59 %	-35.5 %

Quick ratio ranking by company, industry and sector >> Back to AGRX Financial Strength Comparisons >> Go to Compare AGRX Quick Ratio to its Competitors

On the trailing twelve months basis Due to growth in Current Liabilities in the Q2 2024 to $26.23 millions, cumulative Quick Ratio decreased to 0.13 below the Agile Therapeutics Inc average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 460 other companies have achieved higher Quick Ratio than Agile Therapeutics Inc. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the first quarter 2024 from 2421 to 3642.

Explain Quick Ratio?
How much Cash & cash equivalents AGRX�s has?
What are AGRX�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Major Pharmaceutical Preparations Industry	# 461
Healthcare Sector	# 967
Within the Market	# 3642

trailing twelve months Quick Ratio Statistics
High	Average	Low
15.61	4.3	0.13
(Jun 30 2020)		(Jun 30 2024)

Companies with similar Quick Ratio in the quarter ending Jun 30 2024, within Major Pharmaceutical Preparations Industry	Quick Ratio	Jun 30 2024 MRQ Cash & cash equivalent	Jun 30 2024 MRQ Current Liabilities
Quantum Biopharma Ltd	0.30	$ 3.307 Millions	$ 11.099 Millions
Bristol myers Squibb Company	0.29	$ 6,653.000 Millions	$ 23,265.000 Millions
Novartis Ag	0.28	$ 8,155.000 Millions	$ 28,692.000 Millions
Akari Therapeutics Plc	0.28	$ 4.177 Millions	$ 14.736 Millions
Mustang Bio inc	0.28	$ 4.268 Millions	$ 15.062 Millions
Sanofi	0.28	$ 9,144.800 Millions	$ 32,661.440 Millions
Integrated Biopharma Inc	0.27	$ 1.677 Millions	$ 6.123 Millions
Ernexa Therapeutics Inc	0.27	$ 2.586 Millions	$ 9.600 Millions
International Stem Cell Corporation	0.26	$ 1.290 Millions	$ 5.024 Millions
Organon and Co	0.26	$ 704.000 Millions	$ 2,755.000 Millions
Geovax Labs Inc	0.24	$ 1.562 Millions	$ 6.404 Millions
Checkpoint Therapeutics inc	0.23	$ 4.951 Millions	$ 21.419 Millions
Hst Global Inc	0.22	$ 0.005 Millions	$ 0.023 Millions
Cns Pharmaceuticals Inc	0.22	$ 1.492 Millions	$ 6.763 Millions
Summit Therapeutics Inc	0.22	$ 35.941 Millions	$ 165.861 Millions
Stablecoin Development Corporation	0.21	$ 0.751 Millions	$ 3.610 Millions
Galapagos Nv	0.19	$ 71.948 Millions	$ 375.291 Millions
Tonix Pharmaceuticals Holding Corp	0.19	$ 4.156 Millions	$ 22.043 Millions
Cingulate Inc	0.19	$ 0.381 Millions	$ 2.043 Millions
Opko Health Inc	0.18	$ 40.576 Millions	$ 219.553 Millions
Teva Pharmaceutical Industries Limited	0.18	$ 2,258.000 Millions	$ 12,901.300 Millions
Astrazeneca Plc	0.17	$ 8,491.000 Millions	$ 50,381.000 Millions
Pfizer Inc	0.16	$ 7,100.000 Millions	$ 43,819.000 Millions
The Greater Cannabis Company Inc	0.16	$ 0.080 Millions	$ 0.507 Millions
Kuvatris Therapeutics Inc	0.15	$ 0.324 Millions	$ 2.107 Millions
Exicure Inc	0.15	$ 0.528 Millions	$ 3.431 Millions
One World Products Inc	0.15	$ 0.447 Millions	$ 2.925 Millions
Lifecore Biomedical Inc	0.15	$ 8.462 Millions	$ 55.877 Millions
Vireo Growth Inc.	0.15	$ 11.229 Millions	$ 75.246 Millions
Hyperion Defi inc	0.15	$ 2.301 Millions	$ 15.849 Millions

Date modified: 2026-09-26T07:14:03+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.